持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2022/10/07 | 日証協 | 88,700株 | +320.38% | 180,399株 | +207.27% | 151,100株 | +16.75% | 131,092株 | +59.22% |
2022/09/30 | 日証協 | 21,100株 | -49.58% | 58,710株 | +391.71% | 129,426株 | +7.75% | 82,332株 | +35.06% |
2022/09/22 | 日証協 | 41,850株 | -54.05% | 11,940株 | +393.39% | 120,116株 | -16.61% | 60,960株 | -39.34% |
2022/09/16 | 日証協 | 91,071株 | -30.6% | 2,420株 | -90.16% | 144,037株 | +46.79% | 100,500株 | +85.33% |
2022/09/09 | 日証協 | 131,234株 | +12.38% | 24,600株 | -52.94% | 98,127株 | +1.55% | 54,227株 | -18.33% |
2022/09/02 | 日証協 | 116,775株 | -26.24% | 52,276株 | -67.13% | 96,627株 | -5.49% | 66,394株 | -27.11% |
2022/08/26 | 日証協 | 158,325株 | +15.14% | 159,056株 | +410.51% | 102,240株 | +49.76% | 91,090株 | +419.83% |
2022/08/19 | 日証協 | 137,512株 | -4.98% | 31,156株 | +55.45% | 68,267株 | -4.07% | 17,523株 | +4.8% |
2022/08/12 | 日証協 | 144,712株 | +3.73% | 20,043株 | -50.47% | 71,164株 | +11.47% | 16,720株 | -23.52% |
2022/08/05 | 日証協 | 139,512株 | -12.66% | 40,463株 | -67.17% | 63,843株 | -25.73% | 21,861株 | -17.88% |
2022/07/29 | 日証協 | 159,735株 | +102.56% | 123,268株 | +322.15% | 85,958株 | +13.61% | 26,620株 | +21.44% |
2022/07/22 | 日証協 | 78,858株 | -2.88% | 29,200株 | +179.69% | 75,658株 | -7.61% | 21,920株 | -15.73% |
2022/07/15 | 日証協 | 81,198株 | +1.77% | 10,440株 | -58.9% | 81,894株 | -6.51% | 26,012株 | +59.64% |
2022/07/08 | 日証協 | 79,784株 | -27.06% | 25,400株 | -58.22% | 87,594株 | -20.1% | 16,294株 | -19.6% |
2022/07/01 | 日証協 | 109,384株 | -5.16% | 60,800株 | -29.35% | 109,632株 | +2.89% | 20,265株 | -35.53% |
2022/06/24 | 日証協 | 115,336株 | +24.61% | 86,052株 | +694.5% | 106,554株 | +14.75% | 31,432株 | +50.88% |
2022/06/17 | 日証協 | 92,555株 | -37.84% | 10,831株 | -56.83% | 92,854株 | -12.8% | 20,832株 | +62.75% |
2022/06/10 | 日証協 | 148,904株 | +2.62% | 25,091株 | -86.48% | 106,488株 | -3.54% | 12,800株 | -70.57% |
2022/06/03 | 日証協 | 145,107株 | -38.75% | 185,630株 | -66.52% | 110,391株 | -47.38% | 43,500株 | -24.22% |
※株式分割は考慮していませんのでご注意ください。
Page Top